Micro vs. nano: PLGA particles loaded with trimethoprim for instillative treatment of urinary tract infections

被引:12
作者
Brauner, Bernhard [1 ]
Schwarz, Patrik [1 ]
Wirth, Michael [1 ]
Gabor, Franz [1 ]
机构
[1] Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, Althanstr 14, A-1090 Vienna, Austria
关键词
Nanoparticles; Microparticles; Trimethoprim; PLGA; Urinary tract infection; Instillative therapy; BIODEGRADABLE MICROSPHERES; DRUG-RELEASE; NANOPARTICLES; MICROPARTICLES; PATHOGENESIS; GENTAMICIN; SIZE;
D O I
10.1016/j.ijpharm.2020.119158
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recurring infections and increasing resistances continue to complicate treatment of urinary tract infections. To investigate alternative treatment options, trimethoprim loaded micro- (D[4;3] of 1-9 mu m) and nanoparticles (Z-Avg of 200-400 nm) were prepared from two types of poly(D,L-lactic-co-glycolic acid) (PLGA) for instillative therapy. While PLGA 503H microparticles could not be loaded with more than 2.6% trimethoprim, PLGA 2300 entrapped 22%. When preparing nanoparticles, both types displayed an even higher drug load of up to 29% using PLGA 2300, while PLGA 503H drug load stagnated at 10%. After eight hours, drug release from microparticles amounted to 55% (503H) and 35% (2300) whereas total drug release occurred after 8 (503H) and 9 days (2300). In case of nanoparticles, trimethoprim was liberated much faster with 60% after 2 h and a complete release after 24 h from both polymers. PLGA 2300 seems to be the better choice for entrapment of trimethoprim in microparticles considering the drug load. Both polymers, however, seem to be viable options for nanoparticles. Due to the higher overall drug load, nanoparticles seem to be advantageous over microparticles for instillative therapy, especially when prepared with PLGA 2300.
引用
收藏
页数:11
相关论文
共 39 条
[31]   Current knowledge on biodegradable microspheres in drug delivery [J].
Prajapati, Vipul D. ;
Jani, Girish K. ;
Kapadia, Jinita R. .
EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (08) :1283-1299
[32]  
RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
[33]   Mathematical modeling of drug delivery [J].
Siepmann, J. ;
Siepmann, F. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 364 (02) :328-343
[34]   TLR4-mediated expulsion of bacteria from infected bladder epithelial cells [J].
Song, Jeongmin ;
Bishop, Brian L. ;
Li, Guojie ;
Grady, Richard ;
Stapleton, Ann ;
Abraham, Soman N. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (35) :14966-14971
[35]   URINARY-TRACT INFECTIONS - FROM PATHOGENESIS TO TREATMENT [J].
STAMM, WE ;
HOOTON, TM ;
JOHNSON, JR ;
JOHNSON, C ;
STAPLETON, A ;
ROBERTS, PL ;
MOSELEY, SL ;
FIHN, SD .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (03) :400-406
[36]  
Thundimadathil J, 2019, RSC DRUG DISCOV, P503
[37]   Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation [J].
van Nieuwkoop, C. ;
den Exter, P. L. ;
Elzevier, H. W. ;
den Hartigh, J. ;
van Dissel, J. T. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 36 (06) :485-490
[38]  
Williams III R.O., 2007, Encycl. Pharm. Technol., VThird, P2384, DOI [10.1081/E-EPT-120041590, DOI 10.1081/E-EPT-120041590]
[39]   Novel targeted bladder drug-delivery systems: a review [J].
Zacche, Martino Maria ;
Srikrishna, Sushma ;
Cardozo, Linda .
RESEARCH AND REPORTS IN UROLOGY, 2015, 7 :169-178